• Trials and Research

  MS patients treated with Ublituximab show benefits in phase 2 study

  Posted by MS News Today Moderator on June 8, 2018 at 5:52 pm

  The investigative infusion therapy ublituximabis (TG Therapeutics) is now moving into a Phase 3 study. Read more about this new treatment option here: #CMSC2018 – New Phase 2 Data Supports Ublituximab in Effectively Lowering Relapses, Depleting B-cells in MS Patients

  Have you heard of TG Therapeutics or ublituximab? What are your thoughts on this study?

  replied 7 years, 9 months ago 1 Member · 0 Replies
• 0 Replies

Log In to Reply